A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs JKB 122 (Primary)
- Indications Autoimmune hepatitis
- Focus Therapeutic Use
- Acronyms JKB-122AIH
- Sponsors TaiwanJ Pharmaceuticals
- 31 Mar 2018 Planned End Date changed from 1 May 2018 to 1 Dec 2018.
- 31 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.
- 24 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.